Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

Launched by INSTITUT CURIE · Aug 12, 2016

Keywords

ClinConnect Summary

This clinical trial, called RB SFCE 2009, is looking at how to treat children with a specific type of eye cancer called unilateral retinoblastoma after they have had surgery to remove the affected eye (a procedure called enucleation). The goal is to provide the best follow-up treatment based on certain risk factors identified by doctors. Researchers want to see how effective this treatment is in preventing cancer from coming back.

To participate in this study, children must be between 2 months and 10 years old, have been diagnosed with extensive unilateral retinoblastoma, and have had surgery to remove their eye. They should not have received any prior chemotherapy or radiation for cancer. Participants will need to meet certain health criteria to ensure they can safely receive the study treatment. Throughout the trial, families can expect regular check-ups and monitoring to assess how well the treatment is working and to ensure the children's overall health is maintained. If you're considering this trial for your child, it's a chance to contribute to important research that could improve care for future patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Written informed consent - a signed informed consent and/or assent (as age appropriate) will be obtained according to institutional guidelines;
• • 2. Male or female ≥2 months and \<10 years of age at the time of signing the informed consent form;
• • 3. Diagnosis of non familial extensive unilateral retinoblastoma treated by primary enucleation
• 4. In case of post operative chemotherapy, patients must have adequate organ function:
• • Adequate hematopoietic function Neutrophils\>1.0x109/l, Platelets \>100 x 109/l.
• • Adequate hepatic function: grade II NCI CTC
• • Adequate renal function: serum creatinemia \<1.5 x ULN for age with normal creatinine clearance estimated by SCHWARTZ formula
• • Audiometry \< Grade II de Brock.
• • Echocardiography normal in case of high dose cyclophosphamide chemotherapy (3 g/m²).
• • 5. Patients affiliated to a Social Security Regimen or beneficiary of the same
• • 6. No chemotherapy or radiotherapy prior to administration of the first dose of study treatment for retinoblastoma or other tumor types
• • 7. Without medical cons-indication to study drugs.
• Exclusion Criteria:
• • Bilateral and/or familial or trilateral retinoblastoma.
• * Unilateral retinoblastoma with indication of primary chemotherapy before enucleation:
• • One or several surgical risk factors
• • Buphthalmia Exophthalmia.
• • Peri ocular inflammatory signs.
• * Extraocular extension :
• • Radiological retrolaminar extension (more than 3 mm behind the lamina cribrosa) and or meningeal sheat optic nerve extension.
• • Extrascleral extension
• • Lymp nodes extension
• * Unilateral retinoblastoma with possibility of conservative treatment:
• • Metastatic extension at diagnosis
• • One inclusion criteria non observed
• • Uncontrolled medical conditions, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol